{"id":486,"date":"2020-09-28T12:15:05","date_gmt":"2020-09-28T10:15:05","guid":{"rendered":"http:\/\/apmonia-therapeutics.com\/?page_id=486"},"modified":"2025-03-06T10:34:07","modified_gmt":"2025-03-06T09:34:07","slug":"pipeline","status":"publish","type":"page","link":"https:\/\/apmonia-therapeutics.com\/index.php\/pipeline\/","title":{"rendered":"Pipeline"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
<\/div>\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Pipeline<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
\n\t\t\t<\/i>\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\tAP-01<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

Apmonia Therapeutics\u2019 lead program is a peptide-based technology, named AP-01 or TAX2, targeting tumor-overexpressed thrombospondin-1 (TSP-1)<\/b> in order to prevent CD47 receptor <\/b>activation.<\/p>\n

AP-01 acts as a modulator of the tumor-tolerant microenvironment<\/b>, reprogramming highly vascularized tumors into poorly angiogenic ones while concomitantly activating the tumor-inhibiting immune system<\/b>. Thanks to its unique mode of action, AP-01 does not recapitulate the hematologic toxicities related to CD47 blockade, hence reaching the full potential of targeting this axis for cancer therapy.<\/p>\n

Large body of in vivo<\/i> efficacy data support the proof-of-concept for AP-01 use as an anti-cancer therapy. TAX2 activates the adaptive (tumor-specific) immune response, as demonstrated by activation of T-cells, production of interferon gamma and significant tumor reduction<\/b>. The T cell stimulatory activities of AP-01 also make it an excellent candidate for combination therapies in the context of a broad immune-oncology approach.<\/p>\n

Current focus for clinical development is <\/span>ovarian cancer<\/b>,\n an orphan indication, as well as colorectal cancer. Other indications \nincluding glioblastoma and pancreatic cancer will be targeted by the \ncompany.<\/span><\/div><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\tAP-02<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

Antiplatelet drugs are administered to patients to reduce their likelihood of experiencing cardiovascular events<\/b>, such as stroke or myocardial infarction, as well as to delay the rate of peripheral arterial diseases progression. A major drawback from current medications is the increased risk of bleeding<\/b>. Due to this critical safety caveat, these drugs (i.e. aspirin and thienopyridines) are contraindicated in patients with pathological bleeding issues and\/or experiencing surgical procedures.<\/p>

TSP-1 binding to CD47 plays a critical role during platelet activation and thrombosis. Our pioneering results obtained from animals demonstrate that TAX2 peptide should be considered as a new strategy of high therapeutic interest in controlling platelet activation and related thrombotic disorders<\/b>, while being associated with a favorable safety profile and low bleeding risk<\/b>.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t

\n\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t<\/i><\/span>\n\t\t\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t\t\t\tDiscovery candidates<\/a>\n\t\t\t\t\t<\/div>\n\n\t\t\t\t\t

Research efforts around next generation candidates take advantage of strong expertise in protein\/protein interaction analysis as well as molecular design to build a pipeline of highly selective and safer drug candidates for cancer therapy, with the potential to address valuable markets with high unmet need.<\/p><\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Pipeline AP-01 Apmonia Therapeutics\u2019 lead program is a peptide-based technology, named AP-01 or TAX2, targeting tumor-overexpressed thrombospondin-1 (TSP-1) in order to prevent CD47 receptor activation. AP-01 acts as a modulator of the tumor-tolerant microenvironment, reprogramming highly vascularized tumors into poorly angiogenic ones while concomitantly activating the tumor-inhibiting immune system. Thanks to its unique mode of … <\/p>\n

Continue reading “Pipeline”<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"footnotes":""},"class_list":["post-486","page","type-page","status-publish","hentry"],"yoast_head":"\nPipeline - Apmonia therapeutics<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/apmonia-therapeutics.com\/index.php\/pipeline\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pipeline - Apmonia therapeutics\" \/>\n<meta property=\"og:description\" content=\"Pipeline AP-01 Apmonia Therapeutics\u2019 lead program is a peptide-based technology, named AP-01 or TAX2, targeting tumor-overexpressed thrombospondin-1 (TSP-1) in order to prevent CD47 receptor activation. AP-01 acts as a modulator of the tumor-tolerant microenvironment, reprogramming highly vascularized tumors into poorly angiogenic ones while concomitantly activating the tumor-inhibiting immune system. Thanks to its unique mode of … Continue reading "Pipeline"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/apmonia-therapeutics.com\/index.php\/pipeline\/\" \/>\n<meta property=\"og:site_name\" content=\"Apmonia therapeutics\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-06T09:34:07+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/apmonia-therapeutics.com\/wp-content\/uploads\/2020\/07\/white_logo_transparent_background-1024x244.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/index.php\\\/pipeline\\\/\",\"url\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/index.php\\\/pipeline\\\/\",\"name\":\"Pipeline - Apmonia therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/index.php\\\/pipeline\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/index.php\\\/pipeline\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/apmonia-therapeutics.com\\\/wp-content\\\/uploads\\\/2020\\\/07\\\/white_logo_transparent_background-1024x244.png\",\"datePublished\":\"2020-09-28T10:15:05+00:00\",\"dateModified\":\"2025-03-06T09:34:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/index.php\\\/pipeline\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/apmonia-therapeutics.com\\\/index.php\\\/pipeline\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/index.php\\\/pipeline\\\/#primaryimage\",\"url\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/wp-content\\\/uploads\\\/2020\\\/07\\\/white_logo_transparent_background.png\",\"contentUrl\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/wp-content\\\/uploads\\\/2020\\\/07\\\/white_logo_transparent_background.png\",\"width\":3400,\"height\":810},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/index.php\\\/pipeline\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/\",\"name\":\"Apmonia therapeutics\",\"description\":\"contact@apmonia-therapeutics.com\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/apmonia-therapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pipeline - Apmonia therapeutics","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/apmonia-therapeutics.com\/index.php\/pipeline\/","og_locale":"en_US","og_type":"article","og_title":"Pipeline - Apmonia therapeutics","og_description":"Pipeline AP-01 Apmonia Therapeutics\u2019 lead program is a peptide-based technology, named AP-01 or TAX2, targeting tumor-overexpressed thrombospondin-1 (TSP-1) in order to prevent CD47 receptor activation. AP-01 acts as a modulator of the tumor-tolerant microenvironment, reprogramming highly vascularized tumors into poorly angiogenic ones while concomitantly activating the tumor-inhibiting immune system. Thanks to its unique mode of … Continue reading \"Pipeline\"","og_url":"https:\/\/apmonia-therapeutics.com\/index.php\/pipeline\/","og_site_name":"Apmonia therapeutics","article_modified_time":"2025-03-06T09:34:07+00:00","og_image":[{"url":"http:\/\/apmonia-therapeutics.com\/wp-content\/uploads\/2020\/07\/white_logo_transparent_background-1024x244.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/apmonia-therapeutics.com\/index.php\/pipeline\/","url":"https:\/\/apmonia-therapeutics.com\/index.php\/pipeline\/","name":"Pipeline - Apmonia therapeutics","isPartOf":{"@id":"https:\/\/apmonia-therapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/apmonia-therapeutics.com\/index.php\/pipeline\/#primaryimage"},"image":{"@id":"https:\/\/apmonia-therapeutics.com\/index.php\/pipeline\/#primaryimage"},"thumbnailUrl":"http:\/\/apmonia-therapeutics.com\/wp-content\/uploads\/2020\/07\/white_logo_transparent_background-1024x244.png","datePublished":"2020-09-28T10:15:05+00:00","dateModified":"2025-03-06T09:34:07+00:00","breadcrumb":{"@id":"https:\/\/apmonia-therapeutics.com\/index.php\/pipeline\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/apmonia-therapeutics.com\/index.php\/pipeline\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/apmonia-therapeutics.com\/index.php\/pipeline\/#primaryimage","url":"https:\/\/apmonia-therapeutics.com\/wp-content\/uploads\/2020\/07\/white_logo_transparent_background.png","contentUrl":"https:\/\/apmonia-therapeutics.com\/wp-content\/uploads\/2020\/07\/white_logo_transparent_background.png","width":3400,"height":810},{"@type":"BreadcrumbList","@id":"https:\/\/apmonia-therapeutics.com\/index.php\/pipeline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/apmonia-therapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/apmonia-therapeutics.com\/#website","url":"https:\/\/apmonia-therapeutics.com\/","name":"Apmonia therapeutics","description":"contact@apmonia-therapeutics.com","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/apmonia-therapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/apmonia-therapeutics.com\/index.php\/wp-json\/wp\/v2\/pages\/486","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/apmonia-therapeutics.com\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/apmonia-therapeutics.com\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/apmonia-therapeutics.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/apmonia-therapeutics.com\/index.php\/wp-json\/wp\/v2\/comments?post=486"}],"version-history":[{"count":18,"href":"https:\/\/apmonia-therapeutics.com\/index.php\/wp-json\/wp\/v2\/pages\/486\/revisions"}],"predecessor-version":[{"id":1034,"href":"https:\/\/apmonia-therapeutics.com\/index.php\/wp-json\/wp\/v2\/pages\/486\/revisions\/1034"}],"wp:attachment":[{"href":"https:\/\/apmonia-therapeutics.com\/index.php\/wp-json\/wp\/v2\/media?parent=486"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}